JPRN-jRCT2080220075未知2 期
A phase II study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced/metastatic or recurrent non-small cell lung cancer. (JO18396)
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
入选标准
- •Patients with advanced/metastatic or recurrent NSCLC (stage IIIB or IV) who have failed at least one previous chemotherapy regimen.
排除标准
- 未提供
研究者
相似试验
未知
2 期
A phase 2 study, multicenter, open label trial of R1415 (erlotinib hydrochloride) in patients with advanced, metastatic or recurrent non-small cell lung cancer.(JO16565)Advanced or metastatic or recurrent non-small cell lung cancerJPRN-jRCT2080220076Chugai Pharmaceutical Co., Ltd.
进行中（未招募）
1 期
Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001241-84-GBovartis Pharma Services AG23
进行中（未招募）
1 期
Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001241-84-FRovartis Pharma Services AG23
进行中（未招募）
1 期
Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplificatioon-small cell lung cancerMedDRA version: 19.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001241-84-PTovartis Pharma Services AG135
进行中（未招募）
1 期
A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, locally advanced/metastatic nonsmall cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (EGFR TKI) - Study of INC280 alone and in combination with erlotinib vs. chemotherapy in EGFR+/cMET amp NSCLCon-small cell lung cancerMedDRA version: 18.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001241-84-HUovartis Pharma Services AG23